Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Cáncer De Mama Metastásico

P. Beuzeboc
Published 2015 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
El cancer de mama metastasico continua siendo en la mayoria de los casos una enfermedad incurable con una supervivencia global media del orden de 2 anos. Sin embargo, el pronostico varia mucho en funcion de la presentacion y de los subtipos genomicos. Los progresos mas espectaculares realizados estos ultimos anos estan en relacion con los tratamientos dirigidos de los tumores que sobreexpresan el receptor del factor de crecimiento epidermico humano 2 (HER2), el tratamiento de las metastasis oseas (zoledronato, denosumab, vertebroplastias) y los cuidados de soporte, especialmente con la generalizacion de las consultas del dolor, de las unidades de cuidados paliativos y de oncogeriatria, que han permitido una mejora importante de la calidad de vida de las pacientes. El futuro se focaliza en ensayos mas centrados en la biologia de los tumores.
This paper references
10.1007/s10549-011-1594-z
Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden
T. Foukakis (2011)
10.1016/j.breast.2011.09.006
Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design.
W. Eiermann (2012)
10.1016/S0959-8049(11)70145-9
The role of chemotherapy and targeted agents in patients with metastatic breast cancer.
S. Johnston (2011)
10.1016/J.GYOBFE.2003.12.006
Indications de l’Herceptin® dans le traitement du cancer du sein
P. Beuzeboc (2004)
10.1056/NEJMoa1209124
Trastuzumab emtansine for HER2-positive advanced breast cancer.
S. Verma (2012)
10.1200/JCO.2011.39.0708
Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study.
T. Bachelot (2012)
10.1016/S1470-2045(12)70432-1
Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.
T. Bachelot (2013)
10.1200/JCO.2011.36.9215
Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.
S. Kaye (2012)
10.1093/ANNONC/MDM442
Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel.
M. Aapro (2008)
10.1002/(SICI)1097-0142(19960101)77:1<113::AID-CNCR19>3.0.CO;2-8
Infiltrating lobular carcinoma of the breast: Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns
X. Sastre-Garau (1996)
10.1097/CAD.0b013e328349c7bb
Wound healing and catheter thrombosis after implantable venous access device placement in 266 breast cancers treated with bevacizumab therapy
I. Kriegel (2011)
10.1200/JCO.2008.21.4437
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.
K. Blackwell (2010)
10.1200/JCO.2008.18.5397
Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer.
W. Gradishar (2009)
10.1200/JCO.2010.34.1255
RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.
A. Brufsky (2011)
10.1186/1471-2407-11-395
Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death
R. Le Scodan (2011)
10.1056/NEJMoa1113216
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.
J. Baselga (2012)
10.1056/NEJMoa0900212
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
P. Fong (2009)
10.1038/bjc.2011.138
Trastuzumab beyond progression in HER2-positive advanced breast cancer: The Royal Marsden experience
T. Waddell (2011)
10.1684/BDC.2010.1062
Identification en pratique clinique des carcinomes basal-like du sein : des carcinomes « triple zéro/BRCA1-like »
A. Vincent-Salomon (2010)
10.1056/NEJMoa1011418
Iniparib plus chemotherapy in metastatic triple-negative breast cancer.
J. O'Shaughnessy (2011)
10.1200/JCO.2005.05.1383
Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer.
J. Blum (2006)
10.1097/COC.0b013e31819fdf9b
Exemestane as First-Line Therapy in Postmenopausal Women With Recurrent or Metastatic Breast Cancer
Stefan Glück (2010)
10.1002/cncr.25727
Breast cancer recurrence diagnosis suspected on tumor marker rising
L. Champion (2011)
10.1200/JCO.2010.28.0982
RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.
N. Robert (2011)
10.1200/JCO.2010.28.6450
Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.
V. Valero (2011)
10.1093/annonc/mdp373
An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer.
G. Capri (2010)
10.1007/s10549-007-9885-0
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
D. Cameron (2007)
10.1200/JCO.2008.21.1136
Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study.
J. Robertson (2009)
10.1684/BDC.2011.1341
Méningites carcinomateuses des cancers du sein surexprimant HER2 : pour un traitement spécifique ?
M. Gutierrez (2011)
10.1007/s10549-007-9651-3
A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study
P. Cassier (2007)
10.1089/jpm.2010.0539
Use of a subcutaneous implantable pleural port in the management of recurrent malignant pleurisy: five-year experience based on 168 subcutaneous implantable pleural ports.
I. Kriegel (2011)
10.1200/JCO.2005.05.098
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
K. Miller (2005)
10.1684/BDC.2011.1336
Métastases cérébrales des cancers du sein et barrière hématoméningée
V. Diéras (2011)
10.1056/NEJMoa1109653
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
J. Baselga (2012)
10.1200/JCO.2006.08.8575
American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting.
J. Khatcheressian (2006)
10.1093/annonc/mdq430
First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients.
I. Smith (2011)
10.1016/j.clbc.2011.11.001
Intravenous or oral vinorelbine plus capecitabine as first-line treatment in HER2- metastatic breast cancer: joint analysis of 2 consecutive prospective phase II trials.
M. Strada (2012)
10.1200/JCO.2008.19.6618
Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.
G. von Minckwitz (2009)
10.1200/JCO.2005.04.173
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
M. Marty (2005)
10.1093/annonc/mdr587
Screening older cancer patients: first evaluation of the G-8 geriatric screening tool.
C. Bellera (2012)
10.1016/j.ctrv.2011.04.007
Chemotherapy treatment for older women with metastatic breast cancer: what is the evidence?
M. Debled (2011)
10.1002/cncr.10456
HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process
A. Vincent-Salomon (2002)
10.1093/annonc/mdr432
Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis.
J. Cortés (2012)
10.1200/JCO.2009.26.2071
Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.
I. Krop (2010)
10.1684/BDC.2007.0216
[Trastuzumab (Herceptin) and breast cancer: mechanisms of resistance].
V. Diéras (2007)
10.1093/annonc/mdn395
Platinum-based chemotherapy in triple-negative breast cancer.
B. Sirohi (2008)
10.1200/JCO.20.3.719
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.
C. Vogel (2002)
10.12968/JOWC.2011.20.9.403
Necrosis in breast cancer patients with skin metastases receiving bevacizumab-based therapy.
P. Cottu (2011)
10.1016/j.ejca.2011.08.004
Myotax: a phase II trial of docetaxel plus non-pegylated liposomal doxorubicin as first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
E. Curtit (2011)
10.1097/CAD.0b013e32830b58b0
Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report.
H. Stemmler (2008)
10.1200/JCO.2010.30.8213
Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study.
M. Andersson (2011)
10.2967/jnumed.111.093864
The Yield of 18F-FDG PET/CT in Patients with Clinical Stage IIA, IIB, or IIIA Breast Cancer: A Prospective Study
D. Groheux (2011)
10.1200/JCO.2008.21.6457
Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.
D. Miles (2010)
10.1093/annonc/mdq461
Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience.
L. Staudacher (2011)
10.1097/01.COC.0000047126.10522.F9
Anastrozole Versus Tamoxifen as First-Line Therapy in Postmenopausal Patients With Hormone-Dependent Advanced Breast Cancer: A Prospective, Randomized, Phase III Study
A. Milla-Santos (2003)
10.1016/S0140-6736(11)60070-6
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
J. Cortés (2011)
10.1016/j.ctrv.2011.05.005
Oral vinorelbine in metastatic breast cancer: a review of current clinical trial results.
M. Aapro (2012)
10.1016/J.RCL.2007.05.005
Diagnosis of recurrent and metastatic disease using f-18 fluorodeoxyglucose-positron emission tomography in breast cancer.
W. B. Eubank (2007)
10.1126/SCIENCE.3798106
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
D. Slamon (1987)
10.1007/s10549-011-1880-9
Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial
T. Hatschek (2011)
10.1200/JCO.2008.19.5396
Breast cancer with synchronous metastases: survival impact of exclusive locoregional radiotherapy.
R. Le Scodan (2009)
10.1200/JCO.2007.14.4659
Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group.
R. Paridaens (2008)
10.1056/NEJMOA050434
A pooled analysis of bone marrow micrometastasis in breast cancer.
Stephan Braun (2005)
10.1016/j.dld.2011.04.009
Gastric metastasis of breast cancer: a single centre retrospective study.
M. M. Almubarak (2011)
10.1007/s10549-010-1029-2
HER2 status in a population-derived breast cancer cohort: discordances during tumor progression
U. Wilking (2010)
10.1200/JCO.2010.29.5865
Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
H. Burris (2011)
10.1093/annonc/mdr263
High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients.
J.-Y. Pierga (2012)
10.1517/14656566.9.16.2901
Vinorelbine in breast cancer
J. Bonneterre (2008)
10.1200/JCO.2007.11.8604
Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases.
A. Lipton (2007)
10.1200/JCO.2007.10.8399
Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer.
M. Piccart-Gebhart (2008)
10.1016/j.ejca.2011.11.021
Safety of bevacizumab in metastatic breast cancer patients undergoing surgery.
J. Cortés (2012)
10.1016/S1470-2045(09)70315-8
Evolving novel anti-HER2 strategies.
K. Jones (2009)
10.1093/annonc/mdr294
Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab.
D. Lenihan (2012)
10.1200/JCO.2010.28.8415
Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.
A. Di Leo (2010)
10.1056/NEJMOA064320
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
C. Geyer (2006)
10.1200/JCO.2010.33.9507
Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative Group.
Dorte L. Nielsen (2011)
10.1200/JCO.2010.29.7101
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.
A. Stopeck (2010)
10.1200/JCO.2007.10.8407
Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.
T. Burzykowski (2008)
10.1016/j.ejca.2010.01.006
Questionnaires and instruments for a multidimensional assessment of the older cancer patient: what clinicians need to know?
A. Pallis (2010)
10.1200/JCO.2011.35.7376
First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study.
J. Bergh (2012)
10.1200/JCO.2009.24.2024
Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy.
J. Baselga (2010)
10.1038/nrclinonc.2010.154
Triple-negative breast cancer: disease entity or title of convenience?
L. Carey (2010)
10.1056/NEJMOA072113
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.
K. Miller (2007)
10.1200/JCO.2009.25.8707
Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.
H. Burstein (2010)
10.1200/JCO.2002.20.5.1215
Cardiac dysfunction in the trastuzumab clinical trials experience.
A. Seidman (2002)
10.1093/annonc/mdq609
Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper.
M. Aapro (2011)
10.1093/annonc/mdq232
Survival of breast cancer patients with meningeal carcinomatosis.
H. Gauthier (2010)
10.1158/1078-0432.CCR-08-1080
Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer
N. Lin (2009)
10.1097/CAD.0b013e32834860af
Long-term follow-up of patients with metastatic breast cancer: results of a retrospective, single-center analysis from 2000 to 2005
S. Geiger (2011)
10.1016/S0003-3944(01)00526-0
Résections hépatiques pour métastases de cancer du sein : résultats et facteurs pronostiques (65 cas)
M. Pocard (2001)
10.1016/S0003-3944(01)00526-0
Article originalRésections hépatiques pour métastases de cancer du sein : résultats et facteurs pronostiques (65 cas)Liver resections from breast cancer metastasis: results and prognosis factors after hepatic resection in 65 cases.
M. Pocard (2001)
10.1093/annonc/mdr435
Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.
F. Saad (2012)
10.1093/annonc/mdq122
Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer.
A. Chan (2010)
10.1200/JCO.2005.04.937
Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.
W. Gradishar (2005)
10.1200/JCO.2007.13.5822
Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.
S. Chia (2008)
10.1067/MSY.2002.127544
Does aggressive local therapy improve survival in metastatic breast cancer?
S. Khan (2002)
10.1200/JCO.2008.20.6847
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.
B. Kaufman (2009)
10.1093/ANNONC/MDP261
Third consensus on medical treatment of metastatic breast cancer
D. Berthold (2006)
10.3816/CBC.2010.s.009
Challenging clinical scenarios: treatment of patients with triple-negative or basal-like metastatic breast cancer.
S. Greenberg (2010)
10.1016/j.breast.2012.03.003
1st International consensus guidelines for advanced breast cancer (ABC 1).
F. Cardoso (2012)
10.1007/s11060-011-0629-y
Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases
N. Lin (2011)
10.1200/JCO.2005.08.140
Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer.
M. Cristofanilli (2005)
10.1007/s10549-010-1066-x
Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer
H. Wildiers (2010)
10.1007/s10549-011-1767-9
18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques
B. Koolen (2011)
10.1002/cncr.21163
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma
A. Howell (2005)
10.1007/s10549-010-0866-3
Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer
V. Guarneri (2010)
10.1200/JCO.2003.04.194
Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group.
H. Mouridsen (2003)
10.1056/NEJM200103153441101
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D. Slamon (2001)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar